• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性血栓调节蛋白通过刺激凝血酶激活的纤溶抑制物的活化,部分纠正了FVIII缺乏血浆中的过早纤溶缺陷。

Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor.

作者信息

Foley J H, Nesheim M E

机构信息

Department of Biochemistry, Queen's University, Kingston, ON, Canada.

出版信息

J Thromb Haemost. 2009 Mar;7(3):453-9. doi: 10.1111/j.1538-7836.2008.03261.x. Epub 2008 Dec 13.

DOI:10.1111/j.1538-7836.2008.03261.x
PMID:19087221
Abstract

BACKGROUND

Previous work by others has shown that premature clot lysis occurs in plasmas deficient in components of the intrinsic pathway, due to a failure to activate thrombin activatable fibrinolysis inhibitor (TAFI). This suggests the hypothesis that bleeding in hemophilia is due not only to defective coagulation but also enhanced fibrinolysis. These studies were carried out to quantify the extent of TAFI activation over time in normal plasma (NP) and factor VIII deficient plasma (FVIII-DP) and to determine whether soluble thrombomodulin (sTM) can correct the lysis defect in FVIII-DP.

METHODS

The time courses of TAFI activation in both NP and FVIII-DP were monitored after clotting with thrombin, PCPS and Ca(2+), +/- sTM. Clotting and lysis were measured turbidometrically and TAFIa using a functional assay.

RESULTS

Premature lysis that occurs in FVIII-DP is corrected by mixing deficient plasma with 10% NP. However, this does not fully correct the defect in TAFI activation. FVIII-DP must be mixed with up to 50% NP to attain the same TAFIa potential as NP. In FVIII-DP, sTM can correct the defect in TAFIa-dependent prolongation of lysis at low tPA concentrations and partially correct this defect at high tPA concentrations.

CONCLUSIONS

TAFI activation increases as the concentration of FVIII increases. FVIII at a level of 10% fully corrects the lysis defect in spite of the extent of TAFI activation being only one half that obtained with 100% FVIII. In addition, sTM increases TAFI activation sufficiently to correct the premature lysis defect in FVIII-DP.

摘要

背景

其他人之前的研究表明,由于无法激活凝血酶激活的纤维蛋白溶解抑制剂(TAFI),在内源性途径成分缺乏的血浆中会发生过早的凝块溶解。这提示了一种假说,即血友病出血不仅是由于凝血缺陷,还由于纤维蛋白溶解增强。进行这些研究是为了量化正常血浆(NP)和因子VIII缺乏血浆(FVIII-DP)中TAFI随时间的激活程度,并确定可溶性血栓调节蛋白(sTM)是否可以纠正FVIII-DP中的溶解缺陷。

方法

用凝血酶、PCPS和Ca(2+)(±sTM)使NP和FVIII-DP凝血后,监测TAFI激活的时间进程。通过比浊法测量凝血和溶解,并使用功能测定法测量TAFIa。

结果

将缺乏血浆与10%NP混合可纠正FVIII-DP中发生的过早溶解。然而,这并不能完全纠正TAFI激活缺陷。FVIII-DP必须与高达50%NP混合才能达到与NP相同的TAFIa潜力。在FVIII-DP中,sTM可以在低tPA浓度下纠正TAFIa依赖性溶解延长的缺陷,并在高tPA浓度下部分纠正该缺陷。

结论

TAFI激活随着FVIII浓度的增加而增加。尽管TAFI激活程度仅为100%FVIII时的一半,但10%水平的FVIII可完全纠正溶解缺陷。此外,sTM可充分增加TAFI激活,以纠正FVIII-DP中的过早溶解缺陷。

相似文献

1
Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor.可溶性血栓调节蛋白通过刺激凝血酶激活的纤溶抑制物的活化,部分纠正了FVIII缺乏血浆中的过早纤溶缺陷。
J Thromb Haemost. 2009 Mar;7(3):453-9. doi: 10.1111/j.1538-7836.2008.03261.x. Epub 2008 Dec 13.
2
Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.血小板因子 4 可抑制凝血酶激活纤溶抑制物激活剂(TAFI)的血栓调节蛋白依赖性激活。
J Biol Chem. 2011 Jan 7;286(1):502-10. doi: 10.1074/jbc.M110.147959. Epub 2010 Nov 1.
3
Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.凝血酶激活的纤溶抑制物激活与血友病 A 的出血。
Haemophilia. 2012 May;18(3):e316-22. doi: 10.1111/j.1365-2516.2011.02648.x. Epub 2011 Sep 20.
4
Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.因子 XI 缺乏症患者的纤维蛋白溶解抵抗降低。证据表明,凝血酶激活的纤维蛋白溶解抑制剂途径存在非依赖于凝血酶的损伤。
J Thromb Haemost. 2016 Aug;14(8):1603-14. doi: 10.1111/jth.13342. Epub 2016 Jul 18.
5
Evaluation of thrombomodulin/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time.使用组织型纤溶酶原激活剂诱导的血浆凝块溶解时间评估血浆中血栓调节蛋白/凝血酶激活的纤维蛋白溶解抑制剂功能。
Res Pract Thromb Haemost. 2024 May 28;8(4):102463. doi: 10.1016/j.rpth.2024.102463. eCollection 2024 May.
6
Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A.凝血酶激活的纤维蛋白溶解抑制剂途径改变与重度甲型血友病患者的出血表型相关。
J Thromb Haemost. 2020 Feb;18(2):381-389. doi: 10.1111/jth.14656. Epub 2019 Oct 15.
7
Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.凝血依赖性纤溶抑制:羧肽酶 - U的作用及血友病血浆中凝块的过早溶解
Blood. 1996 Nov 15;88(10):3815-23.
8
The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.通过提高凝血酶激活的纤溶抑制物(TAFI)的血浆浓度,可以恢复甲型血友病中纤溶功能的缺陷性下调。
Thromb Haemost. 2001 Oct;86(4):1035-9.
9
FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.FVIII/VWF 复合物比缺乏 VWF 的 FVIII 制剂显示出更强的促凝活性:在血浆和基于细胞的模型中的研究。
Haemophilia. 2020 Jul;26(4):e151-e160. doi: 10.1111/hae.14008. Epub 2020 Apr 23.
10
VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.VhH 抗血栓调节蛋白克隆 1 抑制 TAFI 在流动状态下的人全血中的活化,并增强纤溶。
J Thromb Haemost. 2022 May;20(5):1213-1222. doi: 10.1111/jth.15674. Epub 2022 Mar 11.

引用本文的文献

1
Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme.利伐沙班的纤维蛋白溶解作用是由凝血酶激活的纤溶抑制物介导的,并被酶的天然稳定突变所减弱。
J Thromb Thrombolysis. 2023 Aug;56(2):283-290. doi: 10.1007/s11239-023-02837-3. Epub 2023 Jun 13.
2
Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes.对儿童重度甲型血友病患者进行血栓弹力图和凝血酶生成评估的结果差异很大,且无法预测临床表型。
Res Pract Thromb Haemost. 2022 Sep 26;6(6):e12800. doi: 10.1002/rth2.12800. eCollection 2022 Aug.
3
Fibrin Clot Formation and Lysis in Plasma.
血浆中纤维蛋白凝块的形成与溶解
Methods Protoc. 2020 Sep 25;3(4):67. doi: 10.3390/mps3040067.
4
TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.血友病性关节出血后 TAFI 缺乏可导致血管适应性重塑不良。
JCI Insight. 2019 Oct 3;4(19):128379. doi: 10.1172/jci.insight.128379.
5
Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.血友病 A 小鼠中 TAFI 激活缺陷是关节出血的主要原因。
Blood. 2018 Oct 11;132(15):1593-1603. doi: 10.1182/blood-2018-01-828434. Epub 2018 Jul 19.
6
Bleeding related to disturbed fibrinolysis.与纤维蛋白溶解紊乱相关的出血
Br J Haematol. 2016 Oct;175(1):12-23. doi: 10.1111/bjh.14255. Epub 2016 Aug 1.
7
Advances and challenges in hemophilic arthropathy.血友病性关节病的进展与挑战
Semin Hematol. 2016 Jan;53(1):10-9. doi: 10.1053/j.seminhematol.2015.10.005. Epub 2015 Oct 26.
8
Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.通过超因子Va和因子VIIa联合使用改善血友病伴抑制剂患者的凝血和止血功能。
Thromb Haemost. 2016 Mar;115(3):551-61. doi: 10.1160/TH15-07-0525. Epub 2015 Oct 15.
9
Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A.凝血酶激活的纤溶抑制物激活与血友病 A 的出血。
Haemophilia. 2012 May;18(3):e316-22. doi: 10.1111/j.1365-2516.2011.02648.x. Epub 2011 Sep 20.
10
Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.血小板因子 4 可抑制凝血酶激活纤溶抑制物激活剂(TAFI)的血栓调节蛋白依赖性激活。
J Biol Chem. 2011 Jan 7;286(1):502-10. doi: 10.1074/jbc.M110.147959. Epub 2010 Nov 1.